Direct evidence of edge-to-face CH/π interaction for PAR-1 thrombin receptor activation

Bioorg Med Chem. 2021 Dec 1:51:116498. doi: 10.1016/j.bmc.2021.116498. Epub 2021 Nov 10.

Abstract

Heptapeptide SFLLRNP is a receptor-tethered ligand of protease-activated receptor 1 (PAR-1), and its Phe at position 2 is essential for the aggregation of human platelets. To validate the structural elements of the Phe-phenyl group in receptor activation, we have synthesized a complete set of S/Phe/LLRNP peptides comprising different series of fluorophenylalanine isomers (Fn)Phe, where n = 1, 2, 3, and 5. Phe-2-phenyl was strongly suggested to be involved in the edge-to-face CH/π interaction with the receptor aromatic group. In the present study, to prove this receptor interaction definitively, we synthesized another series of peptide analogs containing (F4)Phe-isomers, with the phenyl group of each isomer possessing only one hydrogen atom at the ortho, meta, or para position. When the peptides were assayed for their platelet aggregation activity, S/(2,3,4,6-F4)Phe/LLRNP and S/(2,3,4,5-F4)Phe/LLRNP exhibited noticeable activity (34% and 6% intensities of the native peptide, respectively), whereas S/(2,3,5,6-F4)Phe/LLRNP was completely inactive. The results indicated that, at the ortho and meta positions but not at the para position, benzene-hydrogen atoms are required for the CH/π interaction to activate the receptor. The results provided a decisive evidence of the molecular recognition property of Phe, the phenyl benzene-hydrogen atom of which participates directly in the interaction with the receptor aromatic π plane.

Keywords: CH/π interaction; Fluorophenylalanine; Phenylalanine; Thrombin receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dose-Response Relationship, Drug
  • Healthy Volunteers
  • Humans
  • Ligands
  • Molecular Structure
  • Peptide Fragments / chemistry
  • Peptide Fragments / pharmacology*
  • Phenylalanine / chemistry
  • Phenylalanine / pharmacology*
  • Platelet Aggregation / drug effects
  • Receptor, PAR-1 / antagonists & inhibitors*
  • Receptor, PAR-1 / metabolism
  • Structure-Activity Relationship

Substances

  • Ligands
  • Peptide Fragments
  • Receptor, PAR-1
  • thrombin receptor peptide SFLLRNP
  • Phenylalanine